# US 2025/0375503 A1 · Method and System for Tuning Hormone Receptors through the Dynamic Intravenous Delivery of a Hormone According to a Target Physiological Cadence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375503 A1
- Document ID: US20250375503A1
- Status: Published application
- Kind: A1
- Application number: 19/014,596
- Filed: 2025-01-09
- Published: 2025-12-11
- Earliest claimed: 2024-06-05
- Assignees: Well Cell Global LLC
- Applicants: Well Cell Global LLC
- Inventors: Scott A. Hepford; Stanley T. Lewis
- Web page: https://patentgrep.com/patent/US20250375503A1

## CPC

- A61K 38/2257: {Prolactin}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- G16H 20/17: delivered via infusion or injection
- A61M 2005/14208: {with a programmable infusion control system, characterised by the infusion program}
- A61M 2202/04: Liquids
- A61M 2205/3303: Using a biosensor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

A system and method for tuning hormone receptors through the dynamic intravenous introduction of a hormone in a manner that mimics a target physiological secretion cadence of that hormone is presented herein. In particular, a dosing model is developed with a desired goal of creating a hormone delivery plan with a dosing waveform that resembles a waveform associated with the target physiological secretion cadence of the hormone. Several bolus delivery specifications, including volume, frequency, and pressure, are dynamically defined such that, over a specified period of time, the bolus introductions create the desired dosing waveform. The dosing model is then executed through a plurality of successive and dynamic intravenous exogenous bolus introductions of the hormone according to the plurality of bolus delivery specifications.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for tuning hormone receptors in a subject, the method comprising:
identifying a hormone which will bind to the hormone receptors;
determining a target physiologic cadence of the hormone;
creating a subject profile for the subject, the subject profile comprising a hormone secretion diagnosis relating to a pre-treatment secretion pattern of the hormone in the subject;
developing a dosing model at least partially based on (a) the target physiologic cadence of the hormone, and (b) the subject profile, wherein the dosing model comprises an identification of the hormone and one or more bolus delivery specifications; and
executing the dosing model through the bolus introductions of the hormone according to the bolus delivery specifications.

### Claim 22 (depends on 21)

The method of claim 21, wherein the bolus delivery specifications comprise one or more of a pressure, a frequency, and a volume associated with each of the bolus introductions.

### Claim 23 (depends on 21)

The method of claim 21, wherein the bolus delivery specifications are selected to generate a bolus delivery waveform that at least partially resembles the target physiologic cadence of the hormone.

### Claim 24 (depends on 21)

The method of claim 21, wherein the bolus delivery specifications are selected to generate a bolus delivery waveform that, when combined with a pre-treatment secretion pattern of the hormone in the subject, at least partially resembles the target physiologic cadence of the hormone.

### Claim 25 (depends on 21)

The method of claim 21, wherein the bolus delivery specifications are selected to generate a bolus delivery waveform, wherein at least one of the bolus delivery specifications is changed within a single wavelength of the bolus delivery waveform.

### Claim 26 (depends on 25)

The method of claim 25, wherein within the single wavelength, volume of at least one of the bolus introductions is different from a volume of at least another one of the bolus introductions.

### Claim 27 (depends on 25)

The method of claim 25, wherein within the single wavelength, pressure of at least one of the bolus introductions is different from a pressure of at least another one of the bolus introductions.

### Claim 28 (depends on 21)

The method of claim 21, further comprising using a pump to intravenously deliver the bolus introductions to the subject, the pump being configured to operate with the bolus delivery specifications.

### Claim 29 (depends on 21)

The method of claim 21, wherein the bolus introductions are intravenous exogenous bolus introductions.

### Claim 30 (depends on 21)

The method of claim 21, wherein the bolus introductions are endogenous bolus introductions.

### Claim 31 (depends on 21)

The method of claim 21, further comprising sensing a physiologic response of the subject to an at least partial execution of the dosing model.

### Claim 32 (depends on 21)

The method of claim 21, further comprising adjusting the dosing model to create a modified dosing model based at least upon a physiologic response of the subject, and executing the modified dosing model through one or more obolus introductions of the hormone.

### Claim 33

A method for tuning hormone receptors in a subject, wherein a hormone binds to the hormone receptor, the method comprising:
determining a target physiologic cadence of the hormone;
developing a dosing model, the dosing model being at least partially based on the target physiologic cadence of the hormone, wherein the dosing model comprises an identification of the hormone and bolus delivery specifications, wherein the bolus delivery specifications comprise at least one of a pressure, a frequency, and a volume;
generating a bolus delivery waveform that at least partially resembles the target physiologic cadence of the hormone based on selection of one or more bolus delivery specifications, wherein at least one of the bolus delivery specifications is changed within a single wavelength of the bolus delivery waveform, and
executing the dosing model through bolus introductions of the hormone according to one or more of the bolus delivery specifications.

### Claim 34 (depends on 33)

The method of claim 33, further comprising obtaining a subject profile, the subject profile comprising a hormone secretion diagnosis relating to a pre-treatment secretion pattern of the hormone in the subject.

### Claim 35 (depends on 33)

The method of claim 33, wherein the dosing model is at least partially based on the subject profile.

### Claim 36 (depends on 33)

The method of claim 33, wherein within the single wavelength, volume of at least one of the bolus introductions is different from a volume of at least another one of the bolus introductions.

### Claim 37 (depends on 33)

The method of claim 33, wherein within the single wavelength, pressure of at least one of the bolus introductions is different from a pressure of at least another one of the bolus introductions.

### Claim 38 (depends on 33)

The method of claim 33, further comprising using a pump to intravenously deliver the bolus introductions to the subject, the pump being configured to operate with one or more of the bolus delivery specifications.

### Claim 39 (depends on 33)

The method of claim 33, further comprising sensing a physiologic response of the subject to an at least partial execution of the dosing model.

### Claim 40 (depends on 33)

The method of claim 33, further comprising adjusting the dosing model to create a modified dosing model based at least upon a physiologic response of the subject, and executing the modified dosing model through a intravenous exogenous bolus introductions of the hormone.

### Claim 41

A system for tuning hormone receptors in a subject, the system comprising:
a processor, a computer-readable memory, and a computer-readable storage;
first program instructions for receiving a subject profile for the subject, the subject profile comprising a hormone secretion diagnosis relating to a pre-treatment secretion pattern of a hormone in the subject; and
second program instructions for executing a dosing model through one or more bolus introductions of the hormone according to bolus delivery specifications, wherein the dosing model is at least partially based on: (a) a target physiologic cadence of the hormone; and
(b) the subject profile, wherein the dosing model comprises one or more of the bolus delivery specifications,
wherein the first and second program instructions are stored on the computer-readable storage for execution by the processor via the computer readable memory.
